Centogene Dirección

Dirección controles de criterios 2/4

El CEO de Centogene's es Kim Stratton , nombrado en Dec 2021, tiene una permanencia de 2.42 años. compensación anual total es €2.84M, compuesta por 24.1% salario y 75.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.25% de las acciones de la empresa, por valor de €119.50K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 5.5 años, respectivamente.

Información clave

Kim Stratton

Chief Executive Officer (CEO)

€2.8m

Compensación total

Porcentaje del salario del CEO	24.1%
Permanencia del CEO	2.5yrs
Participación del CEO	1.2%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	5.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kim Stratton en comparación con los beneficios de Centogene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€3m	€684k	-€36m
Sep 30 2023	n/a	n/a	-€38m
Jun 30 2023	n/a	n/a	-€40m
Mar 31 2023	n/a	n/a	-€40m
Dec 31 2022	€2m	€861k	-€39m

Compensación vs. Mercado: La compensación total de Kim($USD1.64M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de Kim ha aumentado mientras la empresa no es rentable.

CEO

Kim Stratton (62 yo)

2.5yrs

Permanencia

€2,843,000

Compensación

Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board and served as its Interim Chief Executive Officer since December 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kim Stratton	CEO & Member of Management Board	2.5yrs	€2.84m	1.2% € 117.4k
Jose Miguel Rios	CFO, Legal & IT and Member of Management Board	2.3yrs	€1.13m	0.48% € 47.0k
Peter Bauer	Interim MD	1.4yrs	€376.00k	0.079% € 7.7k
Andrin Oswald	Advisor	2.5yrs	€871.00k	sin datos
Ian Rentsch	Chief Commercial Officer & GM of Pharma	1.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 39K se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Souêtre	Independent Member of the Supervisory Board	7.4yrs	€20.00k	sin datos
Hubert Birner	Independent Member of the Supervisory Board	6.9yrs	€22.00k	sin datos
Peer Schatz	Independent Chairman of the Supervisory Board	4.3yrs	€717.00k	0.26% € 25.2k
Jonathan Sheldon	Independent Member of the Supervisory Board	3.5yrs	€97.00k	sin datos
Guido Prehn	Independent Member of the Supervisory Board	7.4yrs	€20.00k	sin datos
Mary Sheahan	Independent Member of the Supervisory Board	1.5yrs	€239.00k	sin datos

5.6yrs

Permanencia media

55yo

Promedio de edad

Junta con experiencia: La junta directiva de 39K se considera experimentada (5.4 años de antigüedad promedio).

Centogene Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Recent updates

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021)

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings released: €0.44 loss per share (vs €0.37 loss in 2Q 2021)

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021)

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.09 loss per share (vs €1.02 loss in FY 2020)

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Second quarter 2021 earnings released

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

New 90-day high: €10.60

Third quarter 2020 earnings released: €0.27 loss per share

Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020

Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport

Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency

New 90-day high: €11.85

Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands

Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation

First half earnings released

New 90-day low: €8.26

Centogene Opens Walk-In COVID-1 Testing Facility At Düsseldorf Airport

Centogene N.V. to Report First Half, 2020 Results on Sep 23, 2020

New 90-day low - €8.96